Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis

A. D. Weinberg, Dennis Bourdette, T. J. Sullivan, M. Lemon, J. J. Wallin, Richard Maziarz, Michael Davey, F. Palida, W. Godfrey, E. Engleman, R. J. Fulton, Halina Offner, Arthur Vandenbark

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

The OX-40 protein was selectively upregulated on encephalitogenic myelin basic protein (MBP)-specific T cells at the site of inflammation during the onset of experimental autoimmune encephalomyelitis (EAE). An OX-40 immunotoxin was used to target and eliminate MBP-specific T cells within the central nervous system without affecting peripheral T cells. When injected in vivo, the OX-40 immunotoxin bound exclusively to myelin-reactive T cells isolated from the CNS, which resulted in amelioration of EAE. Expression of the human OX-40 antigen was also found in peripheral blood of patients with acute graft-versus-host disease and the synovia of patients with rheumatoid arthritis during active disease. The unique expression of the OX-40 molecule may provide a novel therapeutic strategy for eliminating autoreactive CD4+ T cells that does not require prior knowledge of the pathogenic autoantigen.

Original languageEnglish (US)
Pages (from-to)183-189
Number of pages7
JournalNature Medicine
Volume2
Issue number2
DOIs
StatePublished - 1996

Fingerprint

Encephalomyelitis
T-cells
Myelin Sheath
T-Lymphocytes
Antibodies
Immunotoxins
Myelin Basic Protein
Autoimmune Experimental Encephalomyelitis
Synovial Fluid
Autoantigens
Neurology
Graft vs Host Disease
Grafts
Rheumatoid Arthritis
Blood
Central Nervous System
Inflammation
Antigens
Molecules
Proteins

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. / Weinberg, A. D.; Bourdette, Dennis; Sullivan, T. J.; Lemon, M.; Wallin, J. J.; Maziarz, Richard; Davey, Michael; Palida, F.; Godfrey, W.; Engleman, E.; Fulton, R. J.; Offner, Halina; Vandenbark, Arthur.

In: Nature Medicine, Vol. 2, No. 2, 1996, p. 183-189.

Research output: Contribution to journalArticle

Weinberg, A. D. ; Bourdette, Dennis ; Sullivan, T. J. ; Lemon, M. ; Wallin, J. J. ; Maziarz, Richard ; Davey, Michael ; Palida, F. ; Godfrey, W. ; Engleman, E. ; Fulton, R. J. ; Offner, Halina ; Vandenbark, Arthur. / Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. In: Nature Medicine. 1996 ; Vol. 2, No. 2. pp. 183-189.
@article{5ba7c3093f214f00a0fd529edec3557d,
title = "Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis",
abstract = "The OX-40 protein was selectively upregulated on encephalitogenic myelin basic protein (MBP)-specific T cells at the site of inflammation during the onset of experimental autoimmune encephalomyelitis (EAE). An OX-40 immunotoxin was used to target and eliminate MBP-specific T cells within the central nervous system without affecting peripheral T cells. When injected in vivo, the OX-40 immunotoxin bound exclusively to myelin-reactive T cells isolated from the CNS, which resulted in amelioration of EAE. Expression of the human OX-40 antigen was also found in peripheral blood of patients with acute graft-versus-host disease and the synovia of patients with rheumatoid arthritis during active disease. The unique expression of the OX-40 molecule may provide a novel therapeutic strategy for eliminating autoreactive CD4+ T cells that does not require prior knowledge of the pathogenic autoantigen.",
author = "Weinberg, {A. D.} and Dennis Bourdette and Sullivan, {T. J.} and M. Lemon and Wallin, {J. J.} and Richard Maziarz and Michael Davey and F. Palida and W. Godfrey and E. Engleman and Fulton, {R. J.} and Halina Offner and Arthur Vandenbark",
year = "1996",
doi = "10.1038/nm0296-183",
language = "English (US)",
volume = "2",
pages = "183--189",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis

AU - Weinberg, A. D.

AU - Bourdette, Dennis

AU - Sullivan, T. J.

AU - Lemon, M.

AU - Wallin, J. J.

AU - Maziarz, Richard

AU - Davey, Michael

AU - Palida, F.

AU - Godfrey, W.

AU - Engleman, E.

AU - Fulton, R. J.

AU - Offner, Halina

AU - Vandenbark, Arthur

PY - 1996

Y1 - 1996

N2 - The OX-40 protein was selectively upregulated on encephalitogenic myelin basic protein (MBP)-specific T cells at the site of inflammation during the onset of experimental autoimmune encephalomyelitis (EAE). An OX-40 immunotoxin was used to target and eliminate MBP-specific T cells within the central nervous system without affecting peripheral T cells. When injected in vivo, the OX-40 immunotoxin bound exclusively to myelin-reactive T cells isolated from the CNS, which resulted in amelioration of EAE. Expression of the human OX-40 antigen was also found in peripheral blood of patients with acute graft-versus-host disease and the synovia of patients with rheumatoid arthritis during active disease. The unique expression of the OX-40 molecule may provide a novel therapeutic strategy for eliminating autoreactive CD4+ T cells that does not require prior knowledge of the pathogenic autoantigen.

AB - The OX-40 protein was selectively upregulated on encephalitogenic myelin basic protein (MBP)-specific T cells at the site of inflammation during the onset of experimental autoimmune encephalomyelitis (EAE). An OX-40 immunotoxin was used to target and eliminate MBP-specific T cells within the central nervous system without affecting peripheral T cells. When injected in vivo, the OX-40 immunotoxin bound exclusively to myelin-reactive T cells isolated from the CNS, which resulted in amelioration of EAE. Expression of the human OX-40 antigen was also found in peripheral blood of patients with acute graft-versus-host disease and the synovia of patients with rheumatoid arthritis during active disease. The unique expression of the OX-40 molecule may provide a novel therapeutic strategy for eliminating autoreactive CD4+ T cells that does not require prior knowledge of the pathogenic autoantigen.

UR - http://www.scopus.com/inward/record.url?scp=13344283418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13344283418&partnerID=8YFLogxK

U2 - 10.1038/nm0296-183

DO - 10.1038/nm0296-183

M3 - Article

VL - 2

SP - 183

EP - 189

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 2

ER -